203 related articles for article (PubMed ID: 34192954)
1. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature.
Fernandez-Ruiz R; Blank RB; Wu M; Belmont HM
Lupus; 2021 Sep; 30(10):1671-1678. PubMed ID: 34192954
[TBL] [Abstract][Full Text] [Related]
2. A case of C3 glomerulonephritis successfully treated with eculizumab.
Payette A; Patey N; Dragon-Durey MA; Frémeaux-Bacchi V; Le Deist F; Lapeyraque AL
Pediatr Nephrol; 2015 Jun; 30(6):1033-7. PubMed ID: 25796589
[TBL] [Abstract][Full Text] [Related]
3. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
Garg N; Zhang Y; Nicholson-Weller A; Khankin EV; Borsa NG; Meyer NC; McDermott S; Stillman IE; Rennke HG; Smith RJ; Pavlakis M
Nephrol Dial Transplant; 2018 Dec; 33(12):2260-2265. PubMed ID: 29370420
[TBL] [Abstract][Full Text] [Related]
4. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
5. C3 glomerulopathy.
Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
[TBL] [Abstract][Full Text] [Related]
6. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
[TBL] [Abstract][Full Text] [Related]
7. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS
Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277
[TBL] [Abstract][Full Text] [Related]
8. Defining the complement biomarker profile of C3 glomerulopathy.
Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
[TBL] [Abstract][Full Text] [Related]
9. C3 glomerulonephritis with a severe crescentic phenotype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
[TBL] [Abstract][Full Text] [Related]
10. C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis.
Ponticelli C; Calatroni M; Moroni G
Front Med (Lausanne); 2023; 10():1289812. PubMed ID: 38076230
[TBL] [Abstract][Full Text] [Related]
11. Eculizumab and recurrent C3 glomerulonephritis.
Gurkan S; Fyfe B; Weiss L; Xiao X; Zhang Y; Smith RJ
Pediatr Nephrol; 2013 Oct; 28(10):1975-81. PubMed ID: 23689905
[TBL] [Abstract][Full Text] [Related]
12. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?
Alexander MP; Fervenza FC; De Vriese AS; Smith RJH; Nasr SH; Cornell LD; Herrera Hernandez LP; Zhang Y; Sethi S
J Nephrol; 2016 Apr; 29(2):203-209. PubMed ID: 26187133
[TBL] [Abstract][Full Text] [Related]
13. Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation
.
Kim JS; Foster KW; Westphal SG
Clin Nephrol; 2020 Jan; 93(1):51-56. PubMed ID: 31661064
[TBL] [Abstract][Full Text] [Related]
14. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
[TBL] [Abstract][Full Text] [Related]
15. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
[TBL] [Abstract][Full Text] [Related]
16. Anti-factor H antibody-positive C3 glomerulonephritis secondary to poststreptococcal acute glomerulonephritis with diabetic nephropathy.
Oba Y; Mizuno H; Taneda S; Sawai T; Oda T; Ikuma D; Yamanouchi M; Suwabe T; Kono K; Kinowaki K; Ohashi K; Sawa N; Ubara Y
CEN Case Rep; 2024 Apr; 13(2):110-116. PubMed ID: 37452997
[TBL] [Abstract][Full Text] [Related]
17. Systemic lupus erythematosus presenting as lupus erythematosus tumidus and lupus nephritis: a case report.
Hajji M; Gorsane I; Badrouchi S; Litaiem N; Rammeh S; Ben Hamida F; Abderrahim E
J Med Case Rep; 2023 Jun; 17(1):242. PubMed ID: 37312164
[TBL] [Abstract][Full Text] [Related]
18. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
19. Pathology after eculizumab in dense deposit disease and C3 GN.
Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD
J Am Soc Nephrol; 2012 Jul; 23(7):1229-37. PubMed ID: 22677550
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
Wright RD; Bannerman F; Beresford MW; Oni L
BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
